Information Provided By:
Fly News Breaks for December 10, 2019
ABEO
Dec 10, 2019 | 07:23 EDT
Cantor Fitzgerald analyst Kristen Kluska assumed coverage of Abeona Therapeutics with a Neutral rating with a price target of $4, up from $2. While the analyst remains bullish on gene therapy and believes Abeona could form a partnership with earlier-stage programs, she remains on the sidelines due to concerns about the company's lead programs and its current financial status.